Michael Staszel, DO
General Practice · Mount Shasta, CANPI 1417917766
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 159 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $749 and has fallen 54.6% since, to $340 in 2025. Among general practice clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 159 payments — averaging $20.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$680
- AbbVie$387
- Pfizer$304
- Merck$292
- Novo Nordisk$279
- Biohaven Pharmaceuticals, Inc.$165
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,179100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 31 | $680 |
| AbbVie(2 entities) | 17 | $387 |
| Pfizer | 15 | $304 |
| Merck | 16 | $292 |
| Novo Nordisk | 16 | $279 |
| Biohaven Pharmaceuticals, Inc. | 10 | $165 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $145 |
| Sunovion Pharmaceuticals Inc. | 6 | $119 |
| Lilly USA, LLC | 5 | $100 |
| Amgen | 4 | $97 |
| Boehringer Ingelheim | 5 | $92 |
| Eisai Inc. | 6 | $89 |
| Sumitomo Pharma America, Inc. | 3 | $86 |
| Boston Scientific | 1 | $71 |
| Johnson & Johnson | 4 | $69 |
| Exact Sciences | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Indivior Inc. | 1 | $25 |
| Braeburn Inc. | 1 | $21 |
| Dexcom, Inc. | 1 | $19 |
| Alkermes, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
| Ironwood Pharmaceuticals, Inc | 1 | $11 |
How this compares
$3,190 in reported general payments places this provider in the 90th percentile of 12,963 general practice providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 64 | $245,394 |
| OzempicSemaglutide | 113 | $134,969 |
| EliquisApixaban | 99 | $123,157 |
| FarxigaDapagliflozin Propanediol | 81 | $100,073 |
| TrulicityDulaglutide | 50 | $59,440 |
| XareltoRivaroxaban | 30 | $50,076 |
| JanuviaSitagliptin Phosphate | 35 | $45,152 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 60 | $44,054 |
| JardianceEmpagliflozin | 43 | $43,343 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 12 | $41,715 |
| Breo ElliptaFluticasone/Vilanterol | 72 | $33,828 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $31,561 |
| RybelsusSemaglutide | 19 | $27,291 |
| TivicayDolutegravir Sodium | 13 | $26,360 |
| MounjaroTirzepatide | 30 | $24,376 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $279 | $162,260132 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $680 | $153,106156 claims |
| PfizerEliquis, Paxlovid | $304 | $128,874133 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $100 | $83,81680 claims |
| MerckJanuvia, Janumet, Janumet Xr | $292 | $63,27960 claims |
| Johnson & JohnsonXarelto | $69 | $50,07630 claims |
| Boehringer IngelheimJardiance | $92 | $43,34343 claims |
| AbbVieLinzess, Synthroid | $387 | $31,816138 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $86 | $15,39515 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $13,99212 claims |
| Indivior Inc.Suboxone | $25 | $11,32616 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $28 | $9,23215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 12,963 general practice providers in California.
Other general practice in Mount Shasta
- Nathan LiLancaster$5.2M
- Milton McCollSan Jose$4.9M
- Frederic MollRedwood City$2.5M
- Bradley ChingUpland$1.4M
- Eric BrassTorrance$755K
- Marc GeissbergerGreenbrae$583K
- Robert CampbellLong Beach$501K
- Varo BoyerNorth Hills$482K
- Michael MiyasakiSacramento$464K
- Apolinar MadrigalCeres$419K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.